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ABSTRACT
There is currently substantial interest in the therapeutic
properties of probiotic microorganisms as recent re-
search suggests that oral administration of specific
bacterial strains may reduce inflammation and alter the
nature of endogenous microflora in the gastrointestinal
tract. Eosinophils are multifunctional tissue leukocytes,
prominent among the resident cells of the gastrointesti-
nal mucosa that promote local immunity. Recent studies
with genetically alteredmice indicate that eosinophils not
only participate in maintaining gut homeostasis, but that
the absence of eosinophils may have significant impact
on the nature of the endogenous gut microflora and
responses to gut pathogens, notablyClostridium difficile.
Furthermore, in human subjects, there is an intriguing
relationship between eosinophils, allergic inflammation,
and the nature of the lung microflora, notably a distinct
association between eosinophil infiltration and detection
of bacteria of the phylum Actinobacteria. Among topics
for future research, it will be important to determine
whether homeostatic mechanisms involve direct inter-
actions between eosinophils and bacteria or whether
they involve primarily eosinophil-mediated responses to
cytokine signaling in the local microenvironment. Like-
wise, although is it clear that eosinophils can and do
interact with bacteria in vivo, their ability to discern
between pathogenic and probiotic species in various
settings remains to be explored. J. Leukoc. Biol.
100: 000–000; 2016.
Introduction
There is a large and growing interest in the promise of probiotic
microorganisms, defined by the World Health Organization as “live
micro-organisms which, when administered in adequate amounts,
confer a health benefit on the host” [1]. Probiotics, which are
typically select species from the genera Lactobacillus or Bifidobacterium,
currently represent a multibillion dollar commercial component
of the dietary supplements industry. Nonetheless, at this time, the
health benefits conferred by probiotic supplements are not
completely clear, nor are they universally substantiated upon
review of multiple clinical trials ([2–11]).
Probiotics are typically administered orally, and most of our
current understanding and information comes from mouse model
studies and clinical evaluation of their mechanisms of action at the
gastrointestinal tract. Among these mechanisms, probiotic bacteria
may restore balance to the endogenous gut microflora [12–14], the
community of microbes known as the gut microbiome. Other, related
mechanisms under exploration include interactions between pro-
biotic bacteria and the epithelial cells lining the small intestines, as
well as direct and indirect interactions with macrophages, DCs, and T
and B lymphocytes present in the gut mucosa (reviews in [15–18]).
Interestingly, and frequently overlooked, eosinophils are also
among the resident cells of the gut mucosa [19–21] (Fig. 1).
Although eosinophils circulate in small numbers in the
bloodstream and can be recruited to somatic tissues, largely in
response to the eosinophil chemoattractant eotaxin-1 (CCL11),
working in concert with Th2 cytokine provocation [22, 23],
eosinophils are present in the gut at homeostasis [24, 25]. As
such, they are poised to interact with both endogenous
microflora and exogenous probiotic bacteria alone or in concert
with other resident leukocytes.
Much of the literature on probiotics and their relationship with
eosinophils focuses on amelioration of allergic disease, notably
allergic inflammation of the respiratory tract and skin. Among the
confounding issues, there is no clear understanding of what features
of probiotic organisms are crucial to elicit the desired response (e.g.,
bacterial species or strain that is most efficacious, use as prevention
vs. therapy, duration of application, mix and composition of specific
strains, length of therapy, and/or mechanism of action). Although
the World Allergy Organization (WAO) has recently presented
recommendations on probiotics for the prevention and therapy of
eczema [26], there remains no consensus opinion on the impact of
probiotics in allergic disease.
The intent of this review is to examine more closely our current
understanding of the relationship between eosinophils,
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endogenous microbial flora, and probiotic bacteria, with the hopes
of opening the doors to more interest and research in this field.
EOSINOPHILS ARE TISSUE LEUKOCYTES
THAT PROMOTE LOCAL IMMUNITY
Eosinophils are granulocytic leukocytes that were first identified
in 1879 by Paul Ehrlich, who remarked on their unusual staining
properties, including large, refractile cytoplasmic granules that
stained red with coal-tar dyes [27]. Until recently, eosinophils
were considered end-stage, primarily cytotoxic effector cells, with
limited flexibility or biosynthetic capability. However, new
insights into their structure and function, notably regarding
specific chemotactic and degranulation responses, together with
a larger appreciation of the complex and vast array of their
preformed granule cytokines has had a profound impact on this
limited view. Recent studies have indicated that eosinophils are
capable of coordinating local interactions with microorganisms,
as well as with endothelial cells, epithelial cells, and other tissue
leukocytes [22, 23, 28].
Most eosinophils are derived from a self-replenishing source of
hematopoietic precursor cells in the bone marrow and develop
on a continuum through the promyelocytic stage to maturity in
response to cytokines GM-CSF (CSF-2), IL-3, and IL-5 (Fig. 2).
Eosinophils are then released in morphologically mature form
into circulation; after a brief stay (1–2 d), they are recruited to
peripheral tissues. Notably, eosinophils respond to inflammatory
and allergic stimulation and traffic to the lung, skin, esophagus,
liver, gastrointestinal tract, and skeletal muscle.
As prominent components of the gastrointestinal mucosa at
homeostasis, and in response to acute inflammatory stimuli,
eosinophils are situated so as to be capable of interacting directly
with bacteria and bacterial components, both those derived
from commensal microflora and from administered probiotic
bacteria. Eosinophils can present Ags, express PRRs, respond to
pro- and anti-inflammatory mediators, and release preformed
granule proteins and cytokines that can modulate the local
inflammatory response [28–33] (Fig. 3). Selected topics on
eosinophils and local immunity as they relate to interactions with
commensal and pathogenic bacteria are considered in greater
detail below. Numerous reviews and a comprehensive textbook
featuring the basic and clinical biology of eosinophils in health
and disease are available for the interested reader [22, 23, 34].
ENDOGENOUS MICROFLORA AND
PROBIOTIC MICROORGANISMS:
BASIC CONCEPTS
Although the concept of helpful microorganisms probably dates
to Biblical times (discussed in Soccol et al. [35]), Elie
Figure 1. Eosinophils in the small intestines at
homeostasis. Anti-hEPX-mAb (A)– and Anti-
mMBP-mAb (B)–based immunohistochemistry
provides evidence of tissue eosinophils in
normal small-intestinal tissue (ileum) of a
human pediatric subject and a 10-wk-old AKR
strain mice, staining red and brown, respec-
tively. The University of Colorado School of
Medicine Institutional Animal Care and Use
Committee and The Institutional Review
Board at the University of Colorado
(COMIRB) approved these studies. Anti-hEPX
and anti-mMBP were generous gifts from the
laboratories of Dr. James J. Lee and Dr. Nancy
A. Lee.
Figure 2. Eosinophil development and trafficking. Eosinophils develop
in the bone marrow from hematopoietic stem cells in response to
cytokines IL-3, IL-5, and CSF-2. Morphologically mature eosinophils exit
the bone marrow and circulate for a brief time until they exit into
somatic tissues. Eosinophils respond to chemotactic cytokines, such as
eotaxin-1 (CCL11), via its interaction with CCR3 on the eosinophil
surface, and exit circulation. Eosinophils move into the somatic tissue
(such as the gastrointestinal tract) where they can reside for weeks to
months. See text and references [19, 21, 25, 55].
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Metchnikoff [36] was among the first to publish observations on
the relationship between health and the ingestion of active
cultures of the “Bulgarian bacillus.” Interestingly, the text of this
work, entitled The Prolongation of Life also includes a provocative
discussion of the relationship between lifespan and the nature of
the gut microflora in vertebrate species. More recent thoughts on
endogenous flora and prolongation of life can be found in an
essay by Michael Spector [37] entitled “Germs Are Us” in the
“Annals of Science” series in the October 2012 issue of The New
Yorker magazine.
Nearly a century after the publication of the Metchnikoff [36]
treatise on the nature of mammalian gut flora, Lederberg and
McCray [38] introduced the term microbiome as defining “the
ecological community of commensal, symbiotic, and pathogenic
microorganisms that literally share our body space.” Hooper
et al. [39] were among the first to demonstrate this concept at
the molecular level, characterizing the broad-reaching impact of
colonization in germ-free mice with the commensal microor-
ganism Bacteroides thetaiotaomicron. Because many of the organ-
isms found among the normal microflora cannot be readily
cultivated, efforts toward mass-scale identification of normal,
commensal microflora became possible only upon development
of deep-sequencing methodology, with top-down identifications
based on highly conserved sequences of 16S RNA. In 2008, the
U.S. National Institutes of Health embarked on an effort to
characterize the normal human microflora within multiple
accessible body cavities. In 2012, the project group reported [40],
among other findings, that the healthy human gastrointestinal
tract included bacteria primarily of the phyla Firmicutes and
Bacteroidetes, with Proteobacteria as a relatively minor compo-
nent. Among the most intriguing findings of the report was the
observation that there appears to be no “standard” or “defined”
normal gut microbiome, even within their carefully selected
sample population; composition varies significantly among
individuals, although the metabolic functions supported remain
constant.
Probiotic microorganisms are defined as those that confer
health benefits on the recipient host [1]. This definition, on its
own, is functional by nature and highly inclusive, and most recent
clinical and mouse model studies feature one or more gram-
positive bacterial strains from the genera Lactobacillus or
Bifidobacteria. These are not the only bacteria that are likely to be
“probiotic” per se, but specific species from these genera are
among those generally regarded as safe (GRAS) by the U.S. Food
and Drug Administration (http://www.fda.gov). Although there
is not yet a unified synthesis or hierarchy that defines probiotic
action, there are several principles that are used as a basis for
understanding probiotic action, including that the organism (1)
may alter the balance of the gut microflora via colonization
and competition for space, competition for nutrients, and
secretion of favorable (or unfavorable) metabolites and secretory
products; (2) may have a direct impact on intestinal epithelial
cells, including inducing production of protective mucin glyco-
conjugates, limiting production of proinflammatory cytokines,
stabilizing tight junctions, and preventing apoptosis; and (3) may
elicit immune modulation via interactions with resident leuko-
cytes as components of gut-associated lymphoid tissue (GALT) in
the subepithelial mucosal tissue and may interact with macro-
phages, DCs, and T and B lymphocytes at this site, resulting in
the production of immune-modulatory cytokines, including
IL-12, IL-10, and TGF-b; DCs can also sample microbial Ags
directly from the intestinal lumen. These subjects are covered in
depth in several recent reviews [15–18].
Among features common to all gram-positive bacteria, the cell
walls of both Lactobacillus and Bifidobacteria species consist of
multilayered, cross-linked peptidoglycan [41]. The cell walls and
membranes of various Lactobacillus species contain polymers of
D-alanine or glycosyl-substituted wall and membrane teichoic acids,
respectively; the specific nature of the polymers vary among
species and can be influenced by growth conditions [42, 43].
Among the most interesting questions currently under study
include the following: What features of an individual species or of
an individual strain within a bacterial species confer probiotic
function? Can these features be predicted, engineered, and
enhanced [44]? The teichoic acids of Lactobacillus species, which
interact with the host PRR TLR-2, have been identified as
important modulators of probiotic potential. Several groups have
focused on the teichoic acids and have introduced mutations into
the Lactobacillus dltD gene to limit the esterification of D-alanine
to the cell-surface teichoic acids. Interestingly, this manipulation
enhances anti-inflammatory, probiotic properties of these
bacteria in mouse colitis models [45, 46] while impairing
colonization [47].
PROBIOTIC BACTERIA AND THEIR IMPACT
ON ALLERGIC DISEASES
As of this writing, there are scores of independent clinical studies
and numerous reviews and meta-analyses that focus on the
efficacy of probiotic therapy for treatment and/or prevention of
allergic disease [3–7]. For example, following up on the 2007
Cochrane Database Systems meta-analysis, which identified a
reduction in infant eczema among those in probiotic treatment
groups [3], 2 recent meta-analyses, each considering multiple
independent trials involving several thousand subjects, came to
similar conclusions. Specifically, Zuccotti et al. [48] reported that
Figure 3. Eosinophils coordinate local immunomodulatory responses.
Eosinophils impart nuanced responses to their local environment and
have the means to interact both directly and indirectly with probiotic
bacteria and commensal microflora. See text and references [28–33].
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infants receiving probiotic supplementation had a statistically
lower risk of developing eczema than did controls. Likewise,
Cuello-Garcia et al. [4] provided a more extended analysis and
reported that probiotics used by pregnant women, breast-feeding
mothers, and/or infants likewise reduced the risk of developing
eczema, although they cautioned that the quality of the evidence
was low. In contrast, no supporting evidence emerged when
probiotic therapy was evaluated for prevention of asthma or
childhood wheezing [7, 49]. In 2015, the WAO noted specifically
that currently available evidence provided no strong support for
probiotic supplementation as contributing toward reducing the risk
of developing allergy in children overall. However, the committee
highlighted the use of probiotics by infants and pregnant and
breast-feeding mothers, noting a net benefit to those infants at
high risk for developing eczema, albeit via evidence rated as “very
low quality” [26]. Among the confounding issues faced by these
analyses, the individual clinical study designs were often complex
and difficult to compare with one another; it is not clear how long
probiotic administration might be necessary or which probiotic
strain or strains might be most efficacious. At this point, it is not at
all clear what the full impact of probiotic therapy—currently
focused on oral administration of live microorganisms—might be
vis a` vis therapy for allergic disease; further research will certainly
serve to clarify this point.
EOSINOPHILS AND MICROFLORA IN THE
GASTROINTESTINAL TRACT
There is evidence from experimental mouse models indicating
that eosinophils have an influence on the nature of the
normal resident gastrointestinal microflora. Gastrointestinal
eosinophils emerge during fetal life, before the acquisition of gut
microflora [19, 20], and are maintained in the tissue by
homeostatic levels of eotaxin-1 and cytokines from type 2 innate
lymphoid cells [19–21, 24, 25].
Among the most interesting data in support of a role for
eosinophils modulating microbial disease in the gut are recent
findings from Buonomo et al. [50], who demonstrated a
significant role for eosinophils in lethal infection with Clostridium
difficile. Specifically, mice treated with the microbiota-regulated
cytokine IL-25 were protected from lethal infection, an effect that
was dependent on the influx of CD11b+SiglecF+ eosinophils to
the gut. Eosinophil-deficient PHIL mice [51] were not protected
from C. difficile infection by IL-25. Interestingly, mice lacking
eosinophils suffered profound epithelial destruction, unrelated
to levels of IL-4, mucin, or IgA. The results suggested that
eosinophils maintained epithelial barrier function via mecha-
nisms yet to be clarified.
An intriguing counterpoint to these findings are those of
DeSalvo et al. [52], who explored the interplay of IL-33,
eosinophils, and normal microflora in colitis-prone SAMP
mice. The SAMP strain featured in this study (SAMP1/YitFc
[53]) carries a spontaneous mutation and has elevated levels
of intestinal IL-33. In this study, IL-33–mediated eosinophil
infiltration contributed to intestinal pathology, including
profound loss of intact villous structure. Furthermore,
minimal levels of IL-33 were detected in intestinal tissue of
germ-free SAMP mice; introduction of normal microflora via
fecal transplant resulted in induction of IL-33, Th2 cytokine
production, eosinophil infiltration, and inflammatory
pathology.
Although there are many differences that can be accounted for
between these 2 studies, among the most prominent is the fact
that the responses, actions, and impact of eosinophils were
clearly distinct and were influenced by the nature of the local
microenvironment. One cannot see eosinophils in tissue and
state a priori that the outcome will be positive or negative;
eosinophil responses to their environment are clearly highly
nuanced and context dependent [22, 23].
Toward this end, we are still seeking a clearer understanding of
the way in which eosinophils modulate the nature of the
microbiome. In their study featuring mice devoid of eosinophils
(DdblGATA), Chu et al. [54] found that the gut microflora in
these mice was highly irregular, including more bacteria per
milligram of feces, along with a skewed ratio favoring gram-
negative to gram-positive species, with more bacteria of the
phylum Bacteroidetes and fewer Firmicutes than in their wild-
type BALB/c counterparts. Interestingly, Jung et al. [55]
reported the reverse; in a series of experiments with the same
mouse strains (BALB/c and eosinophil-deficient DdblGATA)
under similar conditions (cohoused for at least 3 wk), the
completely opposite results were observed, including a profound
decrease in the proportion of Bacteroidetes and an increase in
the fraction of Firmicutes in the same strain. As we begin to
understand more about factors that may have a profound impact
on the results from any individual microbiome study, it would be
helpful as we move forward to have specific information on the
diet provided to these mice, the specific age and gender, the
frequency of cage changes [56], and factors such as temperature
and dark–light cycles in the vivarium [57]. Apart from the
opposite results, it is not clear whether eosinophils had a direct
impact (e.g., via their granule proteins and cytokines) on the
nature of the microbiome or whether the differences observed
were more indirect, (i.e., eosinophils modulating survival of IgA+
plasma cells, the latter having a direct impact on gut homeostasis
[54] or via support of Peyer’s patches and production of IL-7
[55]). Indeed, as DdblGATA mice are fully devoid of eosinophils,
it cannot be said for certain that the gut eosinophils per se were
the only cells of this lineage contributing to this response.
Other studies suggest that the gut microbiome may have an
impact on eosinophils at sites beyond the immediate gut
microenvironment. Specifically, Suarez-Zamorano et al. [58]
reported that elimination of the endogenous microflora using
either antibiotic treatment or generation of germ-free mice
resulted in expression of Th2 cytokines (IL-4, IL-5, and IL-13)
and recruitment of eosinophils and macrophages to inguinal
subcutaneous (s.c.) tissue in association with the development of
functional beige-fat, a process known to be dependent on
eosinophil-mediated macrophage polarization [59, 60]. The
larger mechanisms linking microflora depletion and eosinophil
accumulation at this more distant site remain unclear.
Moving beyond the small intestines, Fillon et al. [61–63]
explored the microbiome of the esophagus in healthy individuals
and in patients with EoE and gastroesophageal reflux disease, the
latter 2 disorders associated with increased numbers of eosino-
phils in the esophagus, a tissue ordinarily devoid of these cells.
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Among the findings, they noted that absolute bacterial load was
increased in association with both diseases, although eosinophil
infiltration in terms of absolute numbers was not directly
proportional to bacterial load. Bacterial phyla detected included
primarily Firmicutes, Bacteroidetes, and Proteobacteria; bacteria
of the genus Haemophilus were significantly increased in
individuals with untreated EoE compared with healthy controls.
Benitez et al. [64] also examined the esophageal flora and
noted specific enrichment of Proteobacteria in patients with EoE.
The role of the esophageal microflora and its potential
manipulation toward amelioration of disease awaits future study.
EOSINOPHILS, PROBIOTICS, AND
MICROFLORA IN THE RESPIRATORY TRACT
Lung tissue is subject to constant airflow from the exterior as well
as microaspiration of bacteria present in oral secretions and, as
such, is not free of microbes [65, 66]; the healthy lung
microbiome includes primarily bacteria of the phyla Bacteroidetes
and Firmicutes, with prominent contributions from genera
Prevotella, Veillonella, and Streptococcus [65]. As in the gastrointestinal
tract, respiratory diseases, including asthma, COPD, cystic fibrosis,
and pneumonia, are all associated with alterations in the lung
microflora [67–69]. However, specifically with respect to our focus
on eosinophils, a recent study by Huang et al. [70] found that
bacterial numbers (total 16S RNA copy numbers) in brush
extractions from patients with severe asthma were negatively
correlated with total biopsy eosinophil numbers, results
suggesting that higher bacterial burdens were associated with
fewer numbers of eosinophils in the lung tissue. As such, most
of the bacterial phyla identified (primarily Proteobacteria and
Firmicutes) followed similar patterns, with the exception of 2
members of the Actinobacteria (Streptomyces and Propionicimonas),
which correlated positively with eosinophil numbers in tissue.
Of interest, these relationships did not extend to include
correlations of bacterial numbers with eosinophils in blood
or sputum.
A study by Denner et al. [71] compared lung microbiomes in
asthmatics and controls and reported increased species diversity
correlating directly with the percentage of eosinophils in
bronchoalveolar lavage samples. In a similar study featuring
COPD, Sze et al. [72] found that the size of the microbiome was
reduced in association with decreasing lung surface area; as in
the aforementioned study, a strong, positive correlation between
the presence of Actinobacteria and eosinophil infiltration was
reported. However, with a focus on the upper airways, Aurora
et al. [73] characterized the microflora of the nasal cavities and
found a greater bacterial burden, but no specific correlations
with eosinophil numbers, in the tissue in their study of controls
vs. patients with chronic rhinosinusitis. By contrast, in a study of
seasonal allergic rhinitis, Choi et al. [74] reported a significant
correlation between bacterial diversity in the middle meatus with
nasal eosinophil count.
In all of these cases, the focus is the interaction between
eosinophils, eosinophil activity, and the organisms comprising
the local tissue microbiome. With this in mind, our group has
shown that administration of probiotic Lactobacillus species
(phylum Firmicutes) to the lower airways of mice resulted in a
profound reduction in inflammation associated with acute
respiratory virus infection [75, 76]; the long- and short-term
changes to the airway microbiome have not yet been character-
ized. Similar manipulations may prevent eosinophil recruitment
in response to allergen provocation [77, 78].
EOSINOPHILS AND BACTERIA: DIRECT
INTERACTIONS IN VIVO?
Because eosinophils are present at highest concentration in the
small intestines, immediately juxtaposed to the epithelial cells
lining the lumen, the potential for direct interactions among
eosinophils, microflora, orally administered probiotic bacteria,
and/or their components certainly exists.
Toward this end, several groups have explored the expression
of PRRs on human and mouse eosinophils (reviewed in [33]).
Kvarnhammar et al. [79] found that agonists of both NOD1 and
NOD2, the cytosolic receptors for bacterial peptidoglycan
fragments, could activate isolated human eosinophils. By
contrast, it was initially unclear whether human eosinophils
express TLR2 and/or under what specific conditions [33],
although recently, Driss et al. [80] used TLR2-neutralizing Abs to
define the role of this PRR in eosinophil-mediated interactions
with Mycobacterium bovis, suggesting that TLR2 not only exists but
has relevant function. Likewise, to the best of our knowledge, no
one has determined whether eosinophils from the gastrointesti-
nal tract express different PRRs and/or different levels of these
same PRRs than those detected on eosinophils from peripheral
blood and/or whether PRR expression on eosinophils in this
locale changes in response to different states of inflammation or
in disease.
Likewise, many groups have characterized interactions of
eosinophils with bacteria in vitro, primarily those typically
regarded as pathogens (e.g., Escherichia coli, Staphylococcus aureus);
most of these studies predate our understanding of PRRs and
probiotic bacteria. Among these findings, isolated human
eosinophils are capable of direct interactions with bacteria,
including phagocytosis of bacterial pathogens, release of granule
proteins, and generation of reactive oxygen species [81–84].
However, among the more recent findings and perhaps most
relevant to this topic, Yousefi et al. [85] examined the
interactions between eosinophils and bacteria in the gut as well
as ex vivo and found that eosinophils responded by releasing
atypical “nets” known as eosinophil extracellular traps (EETs),
consisting of mitochondrial DNA complexed with granule
cationic proteins. Release was not accompanied by cytolysis or
cell death and could be recapitulated by stimulation of cytokine-
primed, peripheral blood eosinophils with bacterial products,
such as LPS, from gram-negative pathogens. EETs have also been
detected in vivo in EoE, likely in response to barrier dysfunction
and perhaps related to direct exposure of eosinophils to bacteria
in the esophageal lumen [86, 87].
Among the open questions: might eosinophils interact
differently with bacteria that are health promoting, or probiotic?
Might the presence of probiotic bacteria provide signals that
modulate EET formation as well as the release of granule
proteins, cytokines, and reactive oxygen species? Although we
might assume that EET formation relates directly to interactions
Rosenberg et al. Eosinophils, probiotics, and the microbiome
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of bacteria (both probiotic and pathogenic) with eosinophil cell
surface PRRs, we are not aware of any studies that have addressed
this question directly.
Likewise, although there are no studies that address questions
regarding interactions of eosinophils with probiotic bacteria in
vivo, Hosoki et al. [88] found that isolated human eosinophils
released granule stores of eosinophil-derived neurotoxin in
response to the pathogen C. difficile but not in response to the
probiotic bacterium Bifidobacterium bifidum. The mechanisms
underlying this distinction, as well as the way in which all
eukaryotic cells distinguish between these bacterial species,
remains to be elucidated. Furthermore, we have found that
isolated mouse eosinophils can phagocytose the probiotic
bacterial species Lactobacillus reuteri, an action that is associated
with the release of anti-inflammatory cytokine IL-10 (Kraemer
and Rosenberg, unpublished results).
CONCLUSIONS
Eosinophilic leukocytes are unique effector cells with complex
roles in promoting health and homeostasis. They are among the
leukocytes that are prominent in the gastrointestinal mucosa;
data from mouse models suggest that they participate in
maintaining the normal gut microflora and responding to
gastrointestinal pathogens. As such, eosinophils may also respond
to orally administered probiotic microorganisms and contribute
to the resolution of gastrointestinal inflammation. Similarly,
the relationship among eosinophils, lung microflora, and
respiratory inflammation is open to further exploration, notably
the unique association of bacteria of the phylum Actinobacteria
with the degree of eosinophil infiltration in this setting. Future
research will provide information on whether eosinophil-
mediated homeostatic and anti-inflammatory mechanisms in-
volve direct interactions with bacteria and/or responses to
cytokine signaling from epithelial cells and leukocytes in the local
microenvironment.
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